COVID-19: Impact on Human Health
DOI:
https://doi.org/10.37591/rrjoi.v12i1.2796Keywords:
COVID-19, SARS-CoV-2, spike protein, treatment, vaccines candidatesAbstract
Researchers are on the cutting edge of devising the best strategy to combat the SARS-CoV-2 pandemic by studying and exploring the pathogenesis, prevention, and treatment as the world continues to be plagued by an increasing number of confirmed COVID-19 cases. The primary method for detecting the virus is via antigen testing and more accurate molecular tests such as rt PCR using patient samples. The most prevalent treatments for COVID-19 infection include steroidal drugs, monoclonal antibodies therapy, and remdesivir, an anti-viral drug. Despite the fact that these medicines exist and are widely utilised in hospitals all over the world, professionals frequently question their efficacy and usefulness in patients. Furthermore, most targeted therapeutics aim is to disrupt or reduce the interaction of SARS COV-2 spike protein and host cell receptors. In addition to treatment, the most effective technique of stopping the spread of COVID-19 is the development and use of various vaccines candidates which are showing promising results in preventing severe symptoms of the virus. Therefore, more research on COVID-19 pathophysiology, clinical implications, identification (different mutants), diagnosis, and treatment is required, which will help the world to overcome this pandemic.
References
Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. Coronaviruses. 2015; 1282: 1–23.
WHO. Naming the coronavirus disease (COVID-19) and the virus that causes it [Online] Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it (accessed Aug 2020).
Florindo HF, Kleiner R, Vaskovich-Koubi D, Acúrcio RC, Carreira B, Yeini E, Tiram G, Liubomirski Y, Satchi-Fainaro R. Immune-mediated approaches against COVID-19. Nature Nanotechnology. 2020; 15(8): 630–645.
Parlakpinar H, Gunata M. SARS‐COV‐2 (COVID‐19): Cellular and biochemical properties and pharmacological insights into new therapeutic developments. Cell Biochemistry and Function. 2021; 39(1): 10–28.
Islam A, Ahmed A, Naqvi IH, Parveen S. Emergence of deadly severe acute respiratory syndrome coronavirus-2 during 2019–2020. Virusdisease. 2020; 31 (2): 128–136.
Zaim S, Chong JH, Sankaranarayanan V, Harky A. COVID-19 and multiorgan response. Current Problems in Cardiology. 2020; 45(8): 100618.
WHO. COVID-19 weekly epidemiological update. [Online] Available at: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20201110-weekly-epi-update-13.pdf?sfvrsn=24435477_15&download=true (accessed Nov 2020).
Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DS, Du B. Clinical characteristics of 2019 novel coronavirus infection in China. MedRxiv. (Feb 09, 2020). Available Online at: https://www.medrxiv.org/content/10.1101/2020.02.06.
v1#:~:text=Normal%20radiologic%20findings%20are%20present,manifestations)%20predict%20poor%20clinical%20outcomes.
WHO. WHO Coronavirus (COVID-19) dashboard. Available online at: https://covid19.who.int/.
Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA. 2020; 323(11): 1061–1069.
Li W, Shi Z, Yu M, Ren W, Smith C, Epstein JH, Wang H, Crameri G, Hu Z, Zhang H, Zhang J. Bats are natural reservoirs of SARS-like coronaviruses. Science. 2005; 310(5748): 676–679.
Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, Wang W, Song H, Huang B, Zhu N, Bi Y. Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. The Lancet. 2020; 395(10224): 565–574.
Tang X, Wu C, Li X, Song Y, Yao X, Wu X, Duan Y, Zhang H, Wang Y, Qian Z, Cui J. On the origin and continuing evolution of SARS-CoV-2. National Science Review. 2020; 7(6): 1012–1023.
Pascarella G, Strumia A, Piliego C, Bruno F, Del Buono R, Costa F, Scarlata S, Agrò FE. COVID‐19 diagnosis and management: A comprehensive review. Journal of Internal Medicine. 2020; 288(2): 192–206.
Wan S, Xiang YI, Fang W, Zheng Y, Li B, Hu Y, Lang C, Huang D, Sun Q, Xiong Y, Huang X. Clinical features and treatment of COVID‐19 patients in northeast Chongqing. Journal of Medical Virology. 2020; 92(7): 797–806.
Meraj G, Farooq M, Singh SK, Romshoo SA, Nathawat MS, Kanga S. Coronavirus pandemic versus temperature in the context of Indian subcontinent: A preliminary statistical analysis. Environment, Development and Sustainability. 2021; 23(4): 6524–6534.
S Atluri, L Machikanti, JA Hirsch. Expanded umbilical cord mesenchymal stem cells (UC-MSCs) as a therapeutic strategy in managing critically ill COVID-19 patients: The case for compassionate use. Pain Physician. 2020; 23(2): e71–e83.
Chugh RM, Bhanja P, Norris A, Saha S. Experimental models to study COVID-19 effect in stem cells. Cells. 2021; 10(1): 91.
New Drug Approvals. AZD1222 (ChAdOx1), Oxford–AstraZeneca COVID-19 vaccine, COVISHIELD. Available Online at: https://newdrugapprovals.org/2021/03/10/azd1222-chadox1-oxford-astrazeneca-covid-19-vaccine-covishield/.
Cot C, Cacciapaglia G, Islind AS, Óskarsdóttir M, Sannino F. Impact of US vaccination strategy on COVID-19 wave dynamics. Scientific Reports. 2021; 11(1): 1–1.
Menni C, Klaser K, May A, Polidori L, Capdevila J, Louca P, Sudre CH, Nguyen LH, Drew DA, Merino J, Hu C. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID symptom study app in the UK: A prospective observational study. The Lancet Infectious Diseases. 2021; 21(7): 939–949.
Ninja Nerd lectures; 2020. Youtube. COVID-19 Vaccines: MODERNA | PFIZER/BIONTECH | ASTRAZENECA. (Premiered Dec, 2020). Available Online at: https://www.youtube.
com/watch?v=35Idb_lCU4o.
Shimabukuro T, Nair N. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine. JAMA. 2021; 325(8): 780–781.
Pai M, Grill A, Ivers N, Maltsev A, Miller KJ, Razak F, Schull M, Schwartz B, Stall NM, Steiner R, Wilson S. Vaccine-induced prothrombotic immune thrombocytopenia VIPIT following AstraZeneca COVID-19 vaccination. Science briefs of the Ontario covid-19 science advisory table. 2021; 1(17): 10–47326.
Mascellino MT, Di Timoteo F, De Angelis M, Oliva A. Overview of the main anti-SARS-CoV-2 vaccines: mechanism of action, efficacy and safety. Infection and drug resistance. 2021; 14: 3459.
Jones I, Roy P Sputnik V. COVID-19 vaccine candidate appears safe and effective. The Lancet. 2021; 397(10275): 642–643.
Dan JM, Mateus J, Yu K, Hastie K, Faliti CM, Ramirez S. Immunological memory to SARS-CoV-2 assessed for greater than six months after infection. bioRxiv. 2021; 371: 6529.
Varinda. How does Covaxin compare with Covishield, Which is better? (2021-04-08). Available Online at: https://varindia.com/news/how-does-covaxin-compare-with-covishield-which-is-better-.
Dowd KA, Ko SY, Morabito KM, Yang ES, Pelc RS, DeMaso CR, Castilho LR, Abbink P, Boyd M, Nityanandam R, Gordon DN. Rapid development of a DNA vaccine for Zika virus. Science. 2016; 354(6309): 237–240.
Pardi N, Hogan MJ, Pelc RS, Muramatsu H, Andersen H, DeMaso CR, Dowd KA, Sutherland LL, Scearce RM, Parks R, Wagner W. Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. Nature. 2017; 543(7644): 248–251.
FDA. Janssen COVID-19 Vaccine. Available Online at: https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/janssen-covid-19-vaccine.
The Science Advisory Board. Pfizer, BioNTech study 3rd booster of vaccine to protect against variants by the Science Advisory Board staff writers. Available Online at: https://www.scienceboard.net/index.aspx?sec=ser&sub=def&pag=dis&ItemID=2222v.
Blakney AK, McKay PF. Next-generation COVID-19 vaccines: Here come the proteins. The Lancet. 2021; 397(10275): 643–645.
Lavine JS, Bjornstad ON, Antia R. Immunological characteristics govern the transition of COVID-19 to endemicity. Science. 2021; 371(6530): 741–745.
Corey L, Mascola JR, Fauci AS, Collins FS. A strategic approach to COVID-19 vaccine R&D. Science. 2020; 368(6494): 948–950.
Downloads
Published
Issue
Section
License
Declaration and Copyright Transfer Form
(to be completed by authors)
I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.
- I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
- I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
- I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
- I/We also agree to the authorship of the article in the following order:
Author’s name
1. ________________
2. ________________
3. ________________
4. ________________
| We Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal. |
